-83.9%
TTD vs MRNA
+27.9%
-111.8%
-90.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.6% | +0.7% | -0.1% | +0.6% |
| 7D | -7.4% | -8.2% | +0.8% | -7.1% |
| 30D | +3.0% | +125.6% | -122.5% | -3.1% |
| 3M | -27.6% | +197.1% | -224.6% | -34.5% |
| 6M | -49.5% | +148.5% | -198.0% | -53.4% |
| YTD | -63.2% | +363.3% | -426.5% | -69.4% |
| 1Y | -69.7% | +462.0% | -531.7% | -75.7% |
| All | -83.9% | +27.9% | -111.8% | -84.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling